Drug Discovery & DDS– category –
-
Semaglutide More Than Doubles MASH Resolution Likelihood in Meta-Analysis, Stabilizing Fibrosis
AJMC USA Overview A systematic review and meta-analysis published in Medicine reveals that the GLP-1 receptor agonist semaglutide more than doubles the likelihood of MASH (metabolic dysfunction-associated steatohepatitis) resolution with... -
Sanofi Unveils ‘Dual-Targeting Library 2.0’ to Accelerate Novel Bispecific Therapeutic Design
Sanofi France Overview Sanofi has announced its innovative 'Dual-Targeting Library (DTL) 2.0' approach for designing novel bispecific therapeutics. This strategy combines monospecific antibodies and nanobodies to build extensive bispecif... -
Dove Medical Press Reviews Exosome-Inspired Nanocarriers: Next-Gen Drug Delivery for Cancer Therapy
Dove Medical Press UK Overview Dove Medical Press published a review on exosomes as next-generation bio-derived drug delivery systems for cancer therapy. The review emphasizes exosomes' natural ability to cross biological barriers and th... -
Mapping AI Drug Discovery: Key Players Lead Across Target Identification, Generative Design, and Clinical Optimization
Unknown Global Overview A new article maps the AI drug discovery landscape into four key layers: biological target identification, generative molecule design, automated experimentation, and clinical trial optimization. Recursion Pharmace... -
World Economic Forum Names Exosome DDS and Personalized mRNA Cancer Vaccines as Top Emerging Technologies for 2026
World Economic Forum Global Overview The World Economic Forum's 'Top 10 Emerging Technologies of 2026' report details exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines as key innovations. Exosome DDS leverages the... -
Exosome Drug Delivery and Personalized mRNA Cancer Vaccines Emerge as Top Tech Trends for 2026, Showing Promise in Clinical Trials
Today Tech Times Global Overview Today Tech Times reports that exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines are leading technology trends for 2026. Exosome DDS is the focus of over 200 ongoing clinical trials... -
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Navigating the Intricacies of Bispecific Antibody Design: Stability and Manufacturability Challenges Explored
Unknown (attributed to Prassanna Rao and Fränze Vorreiter) USA Overview Prassanna Rao and Fränze Vorreiter detail the design strategies and challenges of bispecific antibodies (BsAbs), which bind two distinct antigens simultaneously. BsA... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
EMA Recommends Approval for New Hypercholesterolemia Drug Evlarco (Obicetrapib / Ezetimibe): A Combination of CETP Inhibitor and Cholesterol Absorption Inhibitor
EMA EU Overview On July 23, 2026, the EMA's CHMP adopted a positive opinion recommending marketing authorization for Evlarco (obicetrapib / ezetimibe). This oral medication is for the treatment of primary hypercholesterolemia or mixed dy...
